# Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

> **NCT05262101** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Advanced High-grade Sarcoma

## Interventions

- **DRUG:** TQB2858 injection

## Key facts

- **NCT ID:** NCT05262101
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-06-28
- **Final completion:** 2023-11-30
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262101, "Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05262101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*